Zura Bio Limited Class A Ordinary Shares (ZURA) is a publicly traded Healthcare sector company. As of May 21, 2026, ZURA trades at $4.10 with a market cap of $390.91M and a P/E ratio of -3.86. ZURA moved +2.38% today. Year to date, ZURA is -14.90%; over the trailing twelve months it is +281.78%. Its 52-week range spans $0.97 to $7.44. Analyst consensus is strong buy with an average price target of $16.40. Rallies surfaces ZURA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Zura Bio Appoints Eisner and Nirula to Board Effective Feb. 21, 2026: Zura Bio appointed Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors effective February 21, 2026. Both leaders bring extensive drug development experience in autoimmune and inflammatory diseases to support the company’s clinical-stage pipeline.
| Metric | Value |
|---|---|
| Price | $4.10 |
| Market Cap | $390.91M |
| P/E Ratio | -3.86 |
| EPS | $-1.06 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.44 |
| 52-Week Low | $0.97 |
| Volume | 2.45K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-68.65M |
| Gross Margin | 0.00% |
5 analysts cover ZURA: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $16.40.